• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (2)
    • A cost-effectiveness analysis of anal cancer screening in HIV-positive women.
    • Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
    • See All 2 Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

A cost-effectiveness analysis of anal cancer screening in HIV-positive women.

A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Low Genit Tract Dis. 2012 Jul; 16(3):275-80.

View in: PubMed

subject areas
  • Adult
  • Age Distribution
  • Anti-Retroviral Agents
  • Anus Neoplasms
  • Combined Modality Therapy
  • Comorbidity
  • Cost-Benefit Analysis
  • Early Detection of Cancer
  • Female
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Incidence
  • Markov Chains
  • Mass Screening
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Proctoscopy
  • Reference Values
  • Risk Assessment
  • Survival Rate
  • United States
  • Young Adult

authors with profiles
  • Kit N. Simpson
  • Gweneth B Lazenby
  • Anne Lintzenich Andrews